{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-049733","form_type":"8-K","ticker":"ACRS","cik":"0001557746","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2026-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.462453+00:00","generated_at":"2026-05-15T02:51:00.984252+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Aclaris reports positive Phase 1a data for ATI-052 (half-life ~45 days) and picks lichen planus for ATI-2138","bullets":["ATI-052 half-life ~45 days; complete inhibition of CCL17/TARC sustained at least 20 weeks post-dose.","Phase 1a ATI-052 well tolerated; no conjunctivitis or safety signals; dose proportional PK observed.","Phase 1b trials in asthma and atopic dermatitis enrolling; top line results expected H2 2026.","Phase 2b for ATI-052 targeting asthma planned for Q4 2026; Phase 2b ATI-2138 in lichen planus starts H2 2026.","ATI-2138 is a potential first-in-class oral ITK/JAK3 inhibitor addressing pathogenic T cells; no FDA-approved LP therapies."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-049733","json":"https://secwatch.observer/filing/0001104659-26-049733.json","markdown":"https://secwatch.observer/filing/0001104659-26-049733.md","text":"https://secwatch.observer/filing/0001104659-26-049733.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557746/000110465926049733/0001104659-26-049733-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557746/000110465926049733/acrs-20260428x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T02:51:00.984252+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}